BRAF and melanoma: Finally, BRAFV600E melanoma cells treated with BRAF or MEK inhibitors significantly decreased RMEL3 expression levels, suggesting RMEL3 as a downstream effector of ERK signaling and as a promising candidate for pharmacological target [19].